XML 19 R8.htm IDEA: XBRL DOCUMENT v3.25.2

DIVESTITURES AND STRATEGIC TRANSACTIONS	6 Months Ended
	Jun. 30, 2025
Discontinued Operations and Disposal Groups [Abstract]
DIVESTITURES AND STRATEGIC TRANSACTIONS	DIVESTITURES AND STRATEGIC TRANSACTIONS Assertio Therapeutics Divestiture On May 9, 2025, the Company transferred all of the equity interests in Assertio Therapeutics to an established purchaser of legacy litigation matters resulting in Assertio Therapeutics being owned by the purchaser’s related company, ATIH Industries, LLC (the “Therapeutics Transaction”). At the closing of the Therapeutics Transaction, Assertio Therapeutics held approximately $8.2 million in cash, insurance and retained a single-digit royalty based on net income derived from INDOCIN. In addition, Assertio Therapeutics retained certain legal liabilities, including those related to opioid litigation (see Note 9. Commitments and Contingencies for further information). As a result of the Therapeutics Transaction, neither the Company nor any of its current subsidiaries are defendants in any opioid-related litigation. The Company recognized a net loss of $8.2 million on the Therapeutics Transaction during the three and six months ended June 30, 2025, which is shown as Loss on Assertio Therapeutics divestiture in the Company’s Condensed Consolidated Statements of Comprehensive Loss. The Therapeutics Transaction is reflected as cash used in investing activities for the six months ended June 30, 2025 on the Company’s Condensed Consolidated Statements of Cash Flows. Otrexup Decommercialization As part of its ongoing commercial portfolio assessment, the Company ceased commercialization of Otrexup beginning in July 2025. As a result of this decision, the Company incurred $3.8 million of expenses during the three and six months ended June 30, 2025. These costs were primarily associated with the write-off of inventory (including inventory held at the Company’s contract manufacturers for Otrexup), the write-off of certain prepaid assets and the recognition of an accrual for the minimum purchase obligation required under the Antares contract (see Note 9. Commitments and Contingencies for further details). The Company recognized $2.5 million of related expenses in Cost of sales and $1.3 million in Selling, general and administrative expenses in the Company’s Condensed Consolidated Statements of Comprehensive Loss during the three and six months ended June 30, 2025 related to ceasing commercialization of Otrexup.

X

- References

No definition available.

+ Details

Name:	us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/205-20/tableOfContent

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 360
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/360/tableOfContent

+ Details

Name:	us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration